Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Findings could pave way for new therapeutic approaches for Friedreich's ataxia

Elevated levels of DNA damage have for the first time been found in the cellular mitochondria and nuclei of patients with the inherited, progressive nervous system disease called Friedreich's ataxia (FRDA), says a multicenter research team led by an expert from the University of Pittsburgh Cancer Institute (UPCI).

18 Jan 2010

Researchers identify ways to predict patients with small-cell lung cancer

Researchers for TGen Clinical Research Services at Scottsdale Healthcare (TCRS) have identified a way to predict which patients with small-cell lung cancer may be resistant to first-line chemotherapy.

18 Jan 2010

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from The University of Texas M. D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

18 Jan 2010

Results from Bionovo's phase 1B clinical trial of Bezielle published

Bionovo, Inc. announced today the publication of their results from its phase 1B clinical trial of Bezielle (BZL101) for metastatic breast cancer. The results of the study are available online in Breast Cancer Research and Treatment and demonstrate that Bezielle continues to be safe and well tolerated with clinical evidence of anticancer activity in a heavily pretreated population of women diagnosed with metastatic breast cancer.

17 Jan 2010

Early immune response needed for 'hit-and-hide' cancer viruses

Retroviruses such as HIV and HTLV-1 don't hit-and-run, they hit-and-hide. They slip into host cells and insert their own DNA into the cell's DNA, and from this refuge they establish an infection that lasts a lifetime.

14 Jan 2010

Study evaluates potential treatments for daytime sleepiness in head-injury patients

Local patients are being sought for a national clinical research study currently investigating a study medication for people who have had a head injury, concussion or bump on the head and feel sleepy or tired during the day.

13 Jan 2010

NCCN to present recommendations on REMS in cancer care at Oncology Summit

Risk evaluation and mitigation strategies (REMS), which can be required by the FDA for drugs or biologics with significant toxicity and/or risks, are emerging as a priority topic for a variety of individuals. The goal of REMS to mitigate known or potential drug risks must be balanced with concerns that such programs may be overly complex and burdensome to physicians and other healthcare providers.

13 Jan 2010

Teenage girls are not receiving HPV vaccine, says report

In 2006, the Food and Drug Administration (FDA) approved the Human Papilloma Virus (HPV) vaccine for girls and women ages 9 to 26. As part of Cervical Cancer Awareness Month in January, experts at The University of Texas M. D. Anderson Cancer Center review what we have learned about this controversial vaccine in the past four years.

13 Jan 2010

Emmi Solutions expands existing suite of cancer-related programs in collaboration with ACS

Emmi Solutions, LLC, creators of Web-based interactive multimedia patient education programs, has collaborated with the American Cancer Society, the nation’s leading voluntary health organization and the preeminent source of cancer information and service, to expand Emmi Solutions’ existing suite of cancer-related programs.

13 Jan 2010

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Brain cancer is the leading cause of cancer death in children. Now a more accurate diagnosis of childhood brain cancers may soon be possible, according to researchers at Huntsman Cancer Institute (HCI) at the University of Utah. The information is published online today in the journal Cancer Research.

13 Jan 2010

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Results of a new study in non-small cell lung cancer showed that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene within the short arm of chromosome 2 of their tumors had a much greater response to a new therapy - an ALK-inhibitor.

13 Jan 2010

Study finds financial ties between clinical study leaders and pharmaceutical companies

Reuters reports that a new study has found "cancer researchers who design clinical trials, analyze or interpret the data, or play other key scientific roles are four times more likely to have financial ties to industry than their counterparts who have lesser roles in these studies, such as recruiting study subjects or collecting the data."

13 Jan 2010

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Theragenics Corporation, a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed® palladium-103 brachytherapy seeds.

13 Jan 2010

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

At least three tumor microRNAs appear to predict when first-line chemotherapy will prove ineffective in some patients with small cell lung cancer, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, held Jan. 11-14, 2010.

13 Jan 2010

Karolinska Institutet receives donation to advance breast cancer research

"We are very happy to be donating money to the fight against breast cancer, especially in light of our own family history," says M-rit Rausing. "Hans's mother and grandmother both died of the disease, and his father, Ruben, put considerable effort into finding a cure. Of course, it's also important when you think that breast cancer is one of the most common diseases."

13 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

SEDLine acquires Hospira's BFM business

SEDLine™, Inc., announced today that it has acquired the brain function monitoring business of Hospira, Inc.. Privately held and backed with an investment from Masimo Corporation, SEDLine, Inc., based in Irvine, California, was formed with the mission to advance neuromonitoring technologies to improve the care of patients under anesthesia or sedation.

13 Jan 2010

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

Clinipace Worldwide, a global technology-driven clinical research organization (CRO), announced today that NitricBio has selected the company to manage and deploy multiple studies in support of medical applications of topical nitric oxide gas (gNO).

13 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Oncology News and Research

Further Reading

Findings could pave way for new therapeutic approaches for Friedreich's ataxia

Researchers identify ways to predict patients with small-cell lung cancer

M. D. Anderson researchers discover mechanism that helps glioblastomas evade immune attack

Results from Bionovo's phase 1B clinical trial of Bezielle published

Early immune response needed for 'hit-and-hide' cancer viruses

Study evaluates potential treatments for daytime sleepiness in head-injury patients

NCCN to present recommendations on REMS in cancer care at Oncology Summit

Teenage girls are not receiving HPV vaccine, says report

Emmi Solutions expands existing suite of cancer-related programs in collaboration with ACS

Research shows missing, mutated genes occur simultaneously in unique set of pediatric brain tumors

Study: Patients with specific oncogenic rearrangements of ALK gene show greater response to new therapy

Study finds financial ties between clinical study leaders and pharmaceutical companies

Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Three tumor microRNAs may help identify chemoresistance in small cell lung cancer patients

Karolinska Institutet receives donation to advance breast cancer research

BDSI to discuss planned BEMA Granisetron IND with the FDA

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

SEDLine acquires Hospira's BFM business

NitricBio chooses Clinipace Worldwide to manage and conduct two phase 3 trials

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News